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Abstract 
Recessive mutations in anoctamin-5 ( ANO5 ) are causative for limb-girdle muscular dystrophy (LGMD) 2 L and non-dysferlin Miyoshi-like 
distal myopathy (MMD3). ANO5 mutations are highly prevalent in European countries; however it is not common in patients of Asian origin, 
and there is no data regarding the Chinese population. We retrospectively reviewed the clinical manifestations and gene mutations of Chinese 
patients with anoctaminopathy. A total of five ANO5 mutations including four novel mutations and one reported mutation were found in four 
patients from three families. No hotspot mutation was found. Three patients presented with presymptomatic hyperCKemia and one patient 
had limb muscle weakness. Muscle imaging of lower limbs showed preferential adductor magnus and medial gastrocnemius involvement. No 
hotspot mutation has been identified in Chinese patients to date. 
© 2019 Elsevier B.V. All rights reserved. 
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t  1. Introduction 
Recessive mutations in anoctamin-5 ( ANO5 ) are
responsible for limb girdle muscular dystrophy (LGMD)
2 L, the most prevalent forms of muscular dystrophy in
Europe [1] , as well as the non-dysferlin Miyoshi-like distal
myopathy (MMD3) [2] . The clinical manifestations of
anoctaminopathy include presymptomatic hyperCKemia,
myalgia, muscle stiffness [3] , recurrent rhabdomyolysis and
limb girdle muscle weakness. Suspected cardiomyopathy
was also reported [4] . Muscle involvement in patients with
anoctaminopathy was usually asymmetric and selective at∗ Corresponding authors. 
E-mail addresses: luosushan@fudan.edu.cn (S. Luo), 
lujiahong@fudan.edu.cn (J. Lu). 
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0960-8966/© 2019 Elsevier B.V. All rights reserved. arly stage with preferential involvement of quadriceps,
amstrings and calves [5,6] . To date, more than 100
isease associated mutations have been reported in ANO5
ene ( https:// databases.lovd.nl/ shared/ variants/ ANO5 ). Two
ecurrent mutations were particularly noted: c.191dupA in
xon 5 was the most common one as the founder mutation
f Northern European origin [6] , while c.2272C > T in exon
0 was the most common mutation in the Finnish population
7] . However, no clear genotype-phenotype correlation was
evealed. 
Only a few cases of anoctaminopathy have been reported in
he Asian population and there is no published data regarding
he Chinese population [8–11] . Here we present the clinical
resentations in four patients with confirmed anoctaminopathy
nd one patient with suspected anoctaminopathy, and
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b  eviewed muscle pathology and muscle magnetic resonance
maging (MRI) in these cases. 
. Materials and methods 
.1. Patients ascertainment 
Patients with a clinical diagnosis of LGMD in Huashan
euromuscular biosample database from 2005–2018 were
eviewed. Most of the patients came from East Mainland
hina and were of Han origin. Inclusion criteria of
uspected LGMD were as follows: (1) progressive limb
irdle muscle weakness; (2) elevated serum creatine
inase(CK) level ( > 170 u/L); (3) electromyogram (EMG)
tudy: myopathic changes. Duchenne muscular dystrophy 
DMD), facioscapulohumeral dystrophy type 1 and type
 (FSHD1 and FSHD2), myotonic dystrophy type 1
nd type 2 (DM1 and DM2), oculopharyngeal muscular
ystrophy (OPMD), inflammatory myopathies and congenital 
yopathies were excluded according to clinical presentation
nd genetic tests when needed. Patients from dominant-
nherited pedigrees were also ruled out. Together with the
GMD cohort, patients with presymptomatic hyperCKemia 
dmitted to the outpatient clinic were also included for further
creening for potential ANO5 gene mutations by targeted
ext-generation sequencing (NGS). 
.2. Genetic analysis 
Genomic DNA was extracted from peripheral blood
sing the High Pure Polymerase chain reaction (PCR)
emplate Preparation Kit (Roche, Basel, CH) according to
he manufacturer’s instructions. The DNA fragments were
nriched by performing solution-based hybridization capture, 
ollowed by sequencing using an Illumina Miseq platform
Illumina, San Diego, CA, USA) with the 2 ×300 bp paired-
nd read module. The hybridization capture procedure was
erformed using the SureSelect Library Prep Kit (Agilent,
anta Clara, CA, USA). The DNA samples were screened
or targeted NGS of 245 genes related to neuromuscular
iseases (Suppl.Tab.1). All mutations identified by NGS were
ubsequently confirmed by Sanger sequencing. 
.3. Clinical data collection 
Medical records of the 4 patients with genetically
onfirmed ANO5 mutations and 1 case with suspected
noctaminopathy were reviewed and evaluated. Physical 
xamination, electrocardiogram (ECG), echocardiogram, 
lectromyography (EMG) and serum CK levels were collected
hen available. Detailed family history, motor milestones
nd personal past medical history were also inquired during
ut-patient follow-up or through phone call follow-up. .4. Muscle imaging 
Muscle MRI of the lower limbs was performed in three
atients (P1, P3 and P4). T1 weighted image (T1WI)
nd short time inversion recovery (STIR) sequences were
mployed on a 3-T MR scanner (Ingenia; Philips Medical
ystems, The Netherlands). Each study was done using a
5-channel head coil, 12-channel posterior coils, and two
6-channel anterior Torso coils. The transverse sections were
nalyzed according to abnormal muscle bulk and signal
ntensities. 
.5. Histology and immunohistochemistry 
Open muscle biopsies were obtained from the biceps
f three cases (P2, P4 and P5). Histochemical and
mmunohistochemical studies including H&E, Gomori 
odified trichrome (GMT), periodic acid-Schiff (PAS) 
nd congo red were performed. The following primary
ntibodies were used for immunohistochemistry with 
tandard procedures: dystrophin (DYS1: Rod domain; DYS2:
-terminus; DYS3: N-terminus, Novocastra, Newcastle 
pon Tyne, UK), dysferlin (NCL-Hamlet, Novocastra), 
arcoglycans (NCL-g-SARC, NCL-a-SARC, NCL-b-SARC, 
ovocastra). 
. Results 
.1. Genetic mutations of ANO5 
Among the 301 LGMD cases and 15 cases with
resymptomatic hyperCKemia, most common subtypes are 
GMD2B (172/301, 57.1%) and LGMD2A (50/301, 16.6%).
ut of a total of 316 individuals, 66 LGMD cases and 6
ases with presymptomatic hyperCKemia were genetically 
ndiagnosed, we identified compound heterozygous or 
omozygous ANO5 gene variants in 5 individuals (P1-5). 
Four patients were considered as confirmed 
noctaminopathy (P1-4, Table 1 ). Five mutations identified
n Patient 1–4 distributed from the middle region to the
-terminal of ANO5 gene ( Fig. 1 ), including 4 novel
utations and one reported mutation. Among these novel
utations, c.1103C > T was predicted to be probably
amaging with a score of 1 by polyphen-2 and the
orresponding amino acid was highly conserved among
ifferent species. Another novel homozygous mutation 
.2498T > G identified in P4 from a consanguineous family
ad a score of 0.995 by polyphen-2. The mutation c.1969C > T
as a novel nonsense mutation leading to premature
ermination. Compound heterozygous mutations including a 
ovel frameshift mutation c.2596_2597del and a reported
issense mutation c.1640G > A were identified in Patient 2
nd Patient 3 from the same family. A novel homozygous
.2423A > T variant was identified in Patient 5 born in a
onsanguineous family ( Fig. 1 ). The variant is predicted to
e possibly damaging by polyphen-2 with a score of 0.880
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Table 1 
Clinical manifestations and mutations of the patients with confirmed anoctaminopathy. 
Confirmed anoctaminopathy 
P1 P2 P3 P4 
Gender M M M F 
Onset age(yrs) – – – 25 
Diagnostic age (yrs) 22 60 59 34 
Phenotype presymptomatic presymptomatic presymptomatic LGMD 
hyperCKemia hyperCKemia hyperCKemia 
Weakness – – – + 
Cardiac problems – + + –
CK (U/L) 2400 2076 Elevated (Specific data not available) 3049 
Muscle MRI (age at MRI(yrs)) GM(24) NA MAGN(59) VM/BF/GM/ MAGN(34) 
Pathology NA Mild NA Mild 
Mutations c.1969C > T c.2596_2597del c.2596_2597del c.2498T > G 
p.Q657X p.K866fs p.K866fs p.M833R 
c.1103C > T c.1640G > A c.1640G > A c.2498T > G p.M833R 
p.T368M p.R547Q p.R547Q 
NA: not available; M male; F female; GM: Gastrocnemius medial; MAGN: adductor magnus; VM: vastus medialis; BF: biceps femoris. 
Fig. 1. Mutations of the 5 patients and their locations on ANO5 gene. Dark and light purple indicate exons; green indicates transmembrane helical domains, 
and blue indicates cytoplasmic or extracellular topological domains. The red text indicates novel mutations. 
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n  and the corresponding amino acid was highly conserved. In
view of the unspecific clinical presentation of patient P5 and
the possibility of this individual having pathogenic variants
in genes not investigated by our NGS panel, in absence of
strong pathogenic evidence for the ANO5 variant found we
classified this patient as with suspected anoctaminopathy. 
3.2. Clinical presentation, serum CK and muscle MRI 
The clinical presentations of these 4 confirmed cases
include presymptomatic hyperCKemia in 3 cases(P1-P3) and
limb girdle muscle weakness in 1 patient (P4). P3 is the
younger brother of P2. One patient (P4) presented limb girdle
muscle weakness, accounting for 0.33% (1/301) of the whole
LGMD population. The clinical, pathological, and molecular
data of the four patients with confirmed anoctaminopathy
were summarized in Table 1 . 
For presymptomatic hyperCkemia cases like P1, P2 and
P3, there was no complaint of weakness, myalgia or muscle
cramps. Muscle strength was normal in all three patients
and only mild calf hypertrophy was demonstrated in P2. P4
experienced progressive limb weakness for 9 years. Physical
examination showed decreased muscle strength graded 4-/5 on
Medical Research Council (MRC) scale of the hip extension,
knee extension and flexion, as well as muscle atrophy of the
quadriceps bilaterally ( Fig. 2 ). No consanguinity was reported
in the patients’ families. Serum CK levels were elevated in
all four patients. For patient 2, elevated serum CK was noticed during
he pre-operative tests for percutaneous coronary intervention
PCI). He reported chest distress and palpitation for 10
ears due to stenocardia. Ventricular premature beats (571
eats), ventricular trigemini (49 times), atrial premature
eats (5823 beats) and supraventricular tachycardia (4 times)
ere recorded during the Holter examination. Interventricular
eptum thickness, enlargement of the left atrium and moderate
iastolic dysfunction of left ventricle were observed on
chocardiogram. The patient had a clinical history of
ypertension for 10 years and diabetes for 12 years with good
ontrol of blood pressure and glucose. Patient 3, the younger
rother of Patient 2, had a medical history of atrial septal
efect. 
Muscle MRI revealed fatty infiltration in medial
astrocnemius ( Fig. 3 A-B), adductor magnus and adductor
ongus ( Fig. 3 C-D) for the presymptomatic cases like P1 and
3. For P4 with LGMD phenotype, fatty infiltration of vastus
ateralis, vastus intermedius, adductor magnus and biceps
emoris in thigh, and medial gastrocnemius in calf ( Fig. 3 E-F)
as observed. 
We also identified one case with suspected
noctaminopathy (P5). This was a 62-year-old male born to
onsanguineous parents, who experienced exercise intolerance
ith post-exercise muscle pain since childhood. Elevated
erum CK was demonstrated in 2015 and it fluctuated from
577 to 3049 U/L. He had difficulty in keeping supine at
ight from the age of 35. Physical examination revealed slight
S. Cai, M. Gao and J. Xi et al. / Neuromuscular Disorders 29 (2019) 628–633 631 
Fig. 2. Clinical aspects of patient 4 showed asymmetric atrophy of quadriceps with the right side being more prominent and atrophy of medial head of 
gastrocnemius. 
Fig. 3. Muscle MRI in lower limbs revealed mild fatty infiltration in medial gastrocnemius in Patient 1 (A: thigh, B: Calf), and adductor magnus and adductor 
longus involvement in Patient 3 (Fig. 3C-D). Fatty infiltration of vastus lateralis, vastus intermedius, adductor magnus and biceps femoris in thigh, and medial 
gastrocnemius in the calf was revealed in Patient 4 (Fig. 3E-F). 
m  
E  
a  
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w
uscle atrophy in his left leg. Muscle strength was normal.
MG showed myogenic changes. ECG showed first-degree
trioventricular block and Echocardiogram showed diastolicysfunction in left ventricle and enlargement of the left
trium. No other explanation for diastolic cardiomyopathy 
as revealed throughout his medical history. 
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Fig. 4. Muscle biopsy of Patient 2,4 and 5. HE staining ( ×200) of patient 2(A), patient 4(B) and patient 5(C) showed mild myopathic changes. Congo red 
staining did not reveal any abnormal changes of patient 2 ( ×100) (D). HE staining ( ×200) (E) and PAS staining ( ×200) (F) of patient 5 showed rimmed 
vacuoles and submembranous vacuoles with positive PAS staining in a few muscle fibers. 
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i  3.3. Muscle pathology 
Muscle biopsy was performed in P2, P4 and P5. Myopathic
changes with mild muscle fiber size variation, scattered
necrotic fibers, regenerating fibers and slightly increased
internal nuclei were observed in muscle biopsies from
all three patients. Congo red staining did not reveal any
significant findings in muscle specimens in P2 and P4
( Fig. 4 ). Muscle biopsy of P5 revealed mild changes with
rimmed vacuoles and submembranous vacuoles with positive
PAS staining in a few muscle fibers. Immunostaining for
dystrophin, sarcoglycan and dysferlin in these 3 patients were
all normal. 
4. Discussion 
We report for the first time a Chinese cohort with
anoctaminopathy. Four patients present with presymptomatic
hyperCKemia and 1 case with LGMD2L. In our single
neuromuscular disorder diagnostic center, LGMD2B and
LGMD2A are the most prevalent forms accounting for 73.8%
in overall LGMD cases. For the remaining 66 LGMD
patients, we diagnosed 4 patients with Sarcoglycanopathies
and 5 patients with LGMD2T, and one case for
LGMD2I/2 J/2 M/2Q/2T, relatively. Current study identified
1 case with confirmed anoctaminopathy (P4), accounting
for only 0.33% (1/301) of the whole LGMD cohort. The
prevalence of ANO5 muscular dystrophy varied in different
regions. It was reported to be 10.5% in a Dutch population
[12] and 11% in a Denmark population [13] , most of whom
presented LGMD or MMD3. In contrast, the prevalence of
ANO5 muscular dystrophy in an Italian cohort was 2.6% [5] .
In other reports, a large proportion of patients with ANO5utations presented with presymptomatic hyperCKemia or
solated cardiac manifestation without muscle weakness [7] .
t is possible that the diagnosis of anoctaminopathy is biased
owards more severe phenotypes and that a proportion of
ilder phenotypes remain undiagnosed. 
Apart from the typical LGMD and MMD3 phenotypes, one
f our genetically confirmed patients (P2) presented cardiac
nvolvement. Cardiac involvement was reported to be part of
he phenotypic spectrum in some cases, The higher prevalence
ompared to healthy age-matched controls and the occurrence
f cardiac abnormalities in young patients of 30–43 years
ld made it reasonable that anoctaminopathy patients had
ncreased risk of cardiac involvement [3,4,13,14] . It is also
nown that ANO5 is highly expressed in cardiac muscle
15] . However, Cardiomyopathy has not been convincingly
onfirmed in anoctaminopathy. In our study, Patient 2
ad long-term hypertension and diabetes type 2, probably
esponsible for his cardiac arrhythmia. 
ANO5 genotypes are diversified among different ethnic
roups. The mutation c.191dupA was reported to be the
ounder mutation of Northern European origin and had a
ery high prevalence in Dutch and Danish population. The
requency was much lower in non-north European populations
uch as Italy or United States [4,5] . It is reported to be cause
 more severe phenotype [16] . In Asian populations, different
utations were reported: c.352delG and c.1025G > A in a
ordanian patient, c.1181–1811_c.1898 + 2287del resulting in
n out-of-frame ANO5 transcript in an Arabic patient and
.2394dup and c.1648C > T in two Japanese patients. In
ur study, the mutation c.1640G > A identified in Patient
 and 3, was previously found in the British population
12] . Up to date, no recurrent mutation has been identified
n Asian populations [8–11] . In our cohort, Patient 4 with
S. Cai, M. Gao and J. Xi et al. / Neuromuscular Disorders 29 (2019) 628–633 633 
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imb-girdle muscle weakness had a homozygous mutation
.2498T > G which was adjacent to the transmembrane
omain ( Fig. 3 ). All the other mutations from presymptomatic
atients(P1-P3) were located inside the topological domains.
hether mutations near the transmembrane domain is more
etrimental to ANO5 expression and functioning, leading to
everer phenotypes needs further investigation. 
With regard to the muscle MRI of our patients with
noctaminopathy, fatty infiltration was confined to certain
uscles at the early stage. In line with previous reports,
dductor magnus was preferentially involved in Patient 3,
hile medial gastrocnemius was selectively involved in
atient 1 and Patient 3. At the more advanced stage as
n Patient 4, fatty infiltration was more widespread on the
high level, while remained selective on the calf level in
edial gastrocnemius. This is in accordance with a 24-year
ollow-up study by Mahjneh et al. [17] . Highly selective
dductor magnus fatty infiltration to a very late stage of the
isease was also reported [7,10,11] . The most distinguishable
maging clue between anoctaminopathy and dysferlinopathy 
as selective involvement of adductor magnus [18] . Thus,
he preferential involvement of adductor magnus and medial
astrocnemius might provide some diagnostic clues for
noctaminopathy. 
In the current study, we concluded that LGMD2L was
elatively rare in Asian LGMD population and there is
o recurrent mutation so far identified in ANO5 gene.
n our cohort of Chinese patients with anoctaminopathy,
resymptomatic hyperCKemia was more frequent than limb-
irdle weakness. However, the number of confirmed cases is
oo small for a final conclusion of the phenotypic spectrum
n Asian populations. 
cknowledgement 
We would like to express our gratitude to all the
articipants and their family members involved in this study.
upplementary materials 
Supplementary material associated with this article can be
ound, in the online version, at doi: 10.1016/j.nmd.2019.06.
05 . 
eferences 
[1] Jarry J , Rioux MF , Bolduc V , Robitaille Y , Khoury V , Thiffault I ,
et al. A novel autosomal recessive limb-girdle muscular dystrophy with
quadriceps atrophy maps to 11p13-p12. Brain 2007;130:368–80 . 
[2] Bolduc V , Marlow G , Boycott KM , Saleki K , Inoue H , Kroon J ,
et al. Recessive mutations in the putative calcium-activated chloride
channel anoctamin 5 cause proximal LGMD2L and distal MMD3
muscular dystrophies. Am J Hum Genet 2010;86(2):213–21 . [3] Papadopoulos C, LaforÊt P, Nectoux J, Stojkovic T, Wahbi K,
Carlier RY, et al. Hyperckemia and myalgia are common presentations
of anoctamin-5-related myopathy in french patients. Muscle Nerve
2017;56(6):1096–100. doi: 10.1002/mus.25608 . 
[4] Liewluck T, Winder TL, Dimberg EL, Crum BA, Heppelmann CJ,
Wang Y, et al. ANO5-muscular dystrophy: clinical, pathological and
molecular findings. Eur J Neurol 2013;20(10):1383–9. doi: 10.1111/ene.
12191 . 
[5] Magri F, Del Bo R, D’Angelo MG, Sciacco M, Gandossini S, Govoni A,
et al. Frequency and characterisation of anoctamin 5 mutations in a
cohort of Italian limb-girdle muscular dystrophy patients. Neuromuscul
Disord 2012;22(11):934–43. doi: 10.1016/j.nmd.2012.05.001 . 
[6] Hicks D, Sarkozy A, Muelas N, Köehler K, Huebner A, Hudson G,
et al. A founder mutation in anoctamin 5 is a major cause of limb-girdle
muscular dystrophy. Brain 2011;134:171–82. doi: 10.1093/ brain/ awq294.
[7] Penttilä S, Palmio J, Suominen T, Raheem O, Evilä A, Muelas
Gomez N, et al. Eight new mutations and the expanding phenotype
variability in muscular dystrophy caused by ANO5. Neurology
2012;78(12):897–903. doi: 10.1212/WNL.0b013e31824c4682. 
[8] Little AA, McKeever PE, Gruis KL. Novel mutations in the anoctamin
5 gene (ANO5) associated with limb-girdle muscular dystrophy 2L.
Muscle Nerve 2013;47(2):287–91. doi: 10.1002/mus.23542. 
[9] Lahoria R, Winder TL, Lui J, Al-Owain MA, Milone M. Novel
ANO5 homozygous microdeletion causing myalgia and unprovoked
rhabdomyolysis in an Arabic man. Muscle Nerve 2014;50(4):610–13.
doi: 10.1002/mus.24302. 
10] Bohlega S, Monies DM, Abulaban AA, Murad HN, Alhindi HN,
Meyer BF. Clinical and genetic features of anoctaminopathy in Saudi
Arabia. Neurosci (Riyadh) 2015;20(2):173–7. doi: 10.17712/nsj.2015.2.
20140547 . 
11] Kadoya M, Ogata K, Suzuki M, Honma Y, Momma K, Yatabe K, et al.
A Japanese male with a novel ANO5 mutation with minimal muscle
weakness and muscle pain till his late fifties. Neuromuscul Disord
2017;27(5):477–80. doi: 10.1016/j.nmd.2017.01.012. 
12] van der Kooi AJ, Ten Dam L, Frankhuizen WS, Straathof CS, van
Doorn PA, de Visser M, et al. ANO5 mutations in the Dutch limb girdle
muscular dystrophy population. Neuromuscul Disord 2013;23(6):456–
60. doi: 10.1016/j.nmd.2013.03.012. 
13] Witting N, Duno M, Petri H, Krag T, Bundgaard H, Kober L, et al.
Anoctamin 5 muscular dystrophy in Denmark: prevalence, genotypes,
phenotypes, cardiac findings, and muscle protein expression. J Neurol
2013;260(8):2084–93. doi: 10.1007/s00415- 013- 6934- y. 
14] Wahbi K, Béhin A, Bécane HM, Leturcq F, Cossée M, Laforêt P, et al.
Dilated cardiomyopathy in patients with mutations in anoctamin 5. Int
J Cardiol 2013;168(1):76–9. doi: 10.1016/j.ijcard.2012.09.070. 
15] Mizuta K , Tsutsumi S , Inoue H , Sakamoto Y , Miyatake K , Miyawaki K ,
et al. Molecular characterization of GDD1/TMEM16E, the gene
product responsible for autosomal dominant gnathodiaphyseal dysplasia.
Biochem Biophys Res Commun 2007;357:126–32 . 
16] Sarkozy A, Hicks D, Hudson J, Laval SH, Barresi R, Hilton-
Jones D, et al. ANO5 gene analysis INA large cohort of patients with
anoctaminopathy: confirmation of male prevalence and high occurrence
of the common exon 5 gene mutation. Hum Mutat 2013;34(8):1111–18.
doi: 10.1002/humu.22342. 
17] Mahjneh I, Bashir R, Kiuru-Enari S, Linssen W, Lamminen A, Visser
Md. Selective pattern of muscle involvement seen in distal muscular
dystrophy associated with anoctamin 5 mutations: a follow-up muscle
MRI study. Neuromuscul Disord 2012;22(Suppl 2):S130–6. doi: 10.
1016/j.nmd.2012.02.007 . 
18] Ten Dam L, van der Kooi AJ, Rövekamp F, Linssen WH, de
Visser M. Comparing clinical data and muscle imaging of DYSF and
ANO5 related muscular dystrophies. Neuromuscul Disord 
2014;24(12):1097–102. doi: 10.1016/j.nmd.2014.07.004. 
